The Latest Breaking News from EXEL

Low P/E S&P stocks stand out as undervalued picks in a volatile market, offering income and potential growth. Amid this backdrop, investors looking for low P/E stocks might consider Merck & Co. (MRK), Verizon Communications (VZ), and The Kroger Co. (KR), as they are well-positioned to deliver steady returns. Read…

Buoyed by encouraging clinical trial results and new advancements, the biotech industry is on a strong upward trajectory. Given the sector’s growing potential, I have highlighted three biotech stocks, Exelixis (EXEL), Gilead Sciences (GILD), and Halozyme Therapeutics (HALO), to consider before their second-quarter earnings report. Read on….

Amid robust global medicine spending, surging biopharma M&A activity, and technological advancements, the biotech industry is set for significant growth this year and beyond. Given the industry’s bright prospects, top biotech stocks Corcept Therapeutics (CORT), Entrada Therapeutics (TRDA), and Exelixis (EXEL) might be ideal buys now to anchor one’s portfolio.…

The biotech industry’s robust growth potential is fueled by scientific advancements, rapid technological adoption, and supportive government initiatives. Thus, you could consider investing in top biotech stocks Exelixis (EXEL), Vertex Pharmaceuticals (VRTX), and Vanda Pharmaceuticals (VNDA) to strengthen your portfolio. Keep reading….

With a wide range of applications across sectors, including health, agriculture, and industrial processing, rapid technological adoption, and government support, the biotech industry’s prospects appear promising. Thus, investors could consider buying biotech stocks Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Incyte (INCY), and Exelixis (EXEL) for substantial gains. Read on….

The biotech industry’s expansion stems from advancements in cutting-edge medical technologies and the growing demand for food biotechnology. Against this backdrop, should you buy Harmony Biosciences Holdings (HRMY), Exelixis (EXEL), and Surrozen (SRZN)? Let’s find out.

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

The biotech industry is growing as a result of steady demand and tech advancements. So, it could be wise to invest in quality biotech stocks Theratechnologies (THTX), Gilead Sciences (GILD), and Exelixis (EXEL) for weekly gains. Read on.

Regeneron preannounced disappointing U.S. Eylea sales, while Exelixis issued light 2024 guidance. REGN stock and EXEL stock slumped.